UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib

Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise

(2014) D. A. Proia et al.   CANCER RESEARCH

Targeting tumour-supportive cellular machineries in anticancer drug development

(2014) Matthias Dobbelstein et al.   NATURE REVIEWS DRUG DISCOVERY

HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer

(2014) R Schulz et al.   Cell Death & Disease

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer

(2013) M. A. Socinski et al.   CLINICAL CANCER RESEARCH

The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification

(2013) Andrew Rowland et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

UDP-Glucuronosyltransferase 1A Compromises Intracellular Accumulation and Anti-Cancer Effect of Tanshinone IIA in Human Colon Cancer Cells

(2013) Miao Liu et al.   PLoS One

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

(2013) Jim Sang et al.   Cancer Discovery

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Pharmacogenetics of P450 oxidoreductase

(2012) Lei Hu et al.   Pharmacogenetics and Genomics

HSP90 inhibitor antagonizing MIF

(2012) Ramona Schulz et al.   OncoImmunology

NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones

(2011) David Siegel et al.   BIOCHEMICAL PHARMACOLOGY

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

(2011) D Li et al.   CELL DEATH AND DIFFERENTIATION

First-Pass Metabolism via UDP-Glucuronosyltransferase: a Barrier to Oral Bioavailability of Phenolics

(2011) Baojian Wu et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

(2011) D. Li et al.   MOLECULAR CANCER RESEARCH

A Mechanistic and Structural Analysis of the Inhibition of the 90-kDa Heat Shock Protein by the Benzoquinone and Hydroquinone Ansamycins

(2011) P. Reigan et al.   MOLECULAR PHARMACOLOGY

Implementing prognostic and predictive biomarkers in CRC clinical trials

(2011) Sandra Van Schaeybroeck et al.   Nature Reviews Clinical Oncology

Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

(2010) J. E. Dancey et al.   CLINICAL CANCER RESEARCH

Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas

(2010) Jochen Gaedcke et al.   GENES CHROMOSOMES & CANCER

A Gene Expression Signature for Chemoradiosensitivity of Colorectal Cancer Cells

(2010) Melanie Spitzner et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells

(2009) N. Gaspar et al.   CANCER RESEARCH

NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

(2008) S. A. Eccles et al.   CANCER RESEARCH